By AP / KWMU
St. Louis, MO – Wyeth hopes to find a buyer for the high-tech facility that will keep on at least some of the 300
workers. The St. Louis Post-Dispatch reports that Wyeth plans to consolidate production at
a plant in Stockholm, Sweden. The Berkeley plant makes ReFacto, a drug used to treat
hemophilia. ReFacto production at the plant will end within two weeks. About two-thirds of employees will be laid off by
mid-February and most of the rest by mid-April.